Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 10/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797205 | 0.92 | CALML3 (0.46) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6797819 | 0.90 | CALML3 (0.46) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6672859 | 0.87 | CALML3 (0.48) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6624455 | 0.87 | MAOA (0.51) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6671547 | 0.86 | CALML3 (0.52) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6795895 | 0.86 | MAOA (0.54) | CALML3CYP2C19MAOAMAOBCYP3A4 | |
| SCHEMBL27573526 | 0.86 | CYP2C19 (0.42) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL27573523 | 0.86 | CYP2C19 (0.42) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6669293 | 0.86 | CALML3 (0.47) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6665107 | 0.86 | CALML3 (0.49) | CALML3CYP2C19CYP2C9MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | claimed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | claimed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | CALML3 4610/4885CYP2C19 39/4885CYP2C9 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.